Earnings call transcript: Abbott Q3 2026 results show growth, but shares fall

Abbott Laboratories reported Q3 2026 adjusted earnings of $1.42 per share, matching estimates, on revenue of $13.01 billion, slightly above forecasts. Sales rose 7% and adjusted EPS increased 9% year-over-year. The company cut full-year sales growth guidance to 6% and announced plans to spin off its nutrition business. Shares fell 2.69% in premarket trading.

Original reporting
Published Oct 21, 2026, 2:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 3:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

Guidance cut and spin‑off announcement triggered a 2.7% pre‑market decline, highlighting investor sensitivity to growth expectations.

02

Market read

The earnings release provides fresh guidance that may prompt short positions or defensive positioning in ABT and related health‑care stocks.

03

What to watch

Margin expansion and strong diagnostics growth may cushion earnings despite lower sales guidance.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Abbott's Q3 2026 earnings were released, showing solid operational performance but a softened outlook.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott reported Q3 earnings matching EPS estimates but cut full-year sales growth guidance to 6% and announced a spin‑off of its nutrition business.

Expected impact

likely pressure as the market prices in the lower growth outlook and execution risk of the nutrition spin‑off

Evidence & confidence

Revenue beat was modest; guidance reduction is the primary catalyst driving the 2.7% pre‑market decline.

Market effects

Healthcare sector may see slight pullback as investors reassess growth expectations for diversified med‑tech firms.

U.S. large‑cap health stocks could face modest weakness in early trade.

Limited; impact confined to U.S. equities and health‑care investors.

Counterpoint

The spin‑off could unlock value in the nutrition unit, offering a longer‑term upside if execution succeeds.

Key entities

  • Abbott Laboratories

    U.S. healthcare conglomerate reporting Q3 results and announcing a nutrition business spin‑off.

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.